Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatic Artery Infusional Floxuridine With Systemic Chemotherapy in Pancreatic Cancer Liver Metastases
NCT03856658Phase 2Active, not recruiting
- Sponsor
- Corewell Health
- Start
- Feb 2019
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of floxuridine in pancreatic adenocarcinoma (PDAC), sponsored by Corewell Health. Started Feb 2019; status: active, not recruiting.
02
Drugs
floxuridine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03856658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03856658.